HK1252062A1 - Nut中線癌的治療 - Google Patents

Nut中線癌的治療

Info

Publication number
HK1252062A1
HK1252062A1 HK18111394.9A HK18111394A HK1252062A1 HK 1252062 A1 HK1252062 A1 HK 1252062A1 HK 18111394 A HK18111394 A HK 18111394A HK 1252062 A1 HK1252062 A1 HK 1252062A1
Authority
HK
Hong Kong
Prior art keywords
treatment
midline carcinoma
nut midline
nut
carcinoma
Prior art date
Application number
HK18111394.9A
Other languages
English (en)
Inventor
S‧B‧蘭多
M‧H‧卡格依
Original Assignee
騰沙治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 騰沙治療公司 filed Critical 騰沙治療公司
Publication of HK1252062A1 publication Critical patent/HK1252062A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18111394.9A 2015-06-26 2018-09-05 Nut中線癌的治療 HK1252062A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26

Publications (1)

Publication Number Publication Date
HK1252062A1 true HK1252062A1 (zh) 2019-05-10

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111394.9A HK1252062A1 (zh) 2015-06-26 2018-09-05 Nut中線癌的治療

Country Status (14)

Country Link
US (1) US20180193350A1 (zh)
EP (1) EP3314005A1 (zh)
JP (1) JP2018520124A (zh)
KR (1) KR20180035785A (zh)
CN (1) CN107787227A (zh)
AR (1) AR105124A1 (zh)
AU (1) AU2016283020A1 (zh)
BR (1) BR112017028178A2 (zh)
CA (1) CA2989313A1 (zh)
HK (1) HK1252062A1 (zh)
IL (1) IL256186A (zh)
MA (1) MA42249A (zh)
MX (1) MX2017016337A (zh)
WO (1) WO2016210275A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
CN104311562B (zh) 2010-05-14 2017-07-04 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法
JP6637884B2 (ja) 2013-11-08 2020-01-29 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
MX2016011160A (es) 2014-02-28 2017-04-27 Tensha Therapeutics Inc Tratamiento de afecciones asociadas con la hiperinsulinemia.
SG11201703414VA (en) 2014-10-27 2017-05-30 Tensha Therapeutics Inc Bromodomain inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
RS54645B1 (en) 2009-11-05 2016-08-31 Glaxosmithkline Llc BENZODIAZEPINE AS A BROMODOMEN INHIBITOR
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
JP5524343B2 (ja) 2009-11-05 2014-06-18 グラクソスミスクライン エルエルシー ベンゾジアゼピンブロモドメイン阻害剤
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
CN104311562B (zh) * 2010-05-14 2017-07-04 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
MX2016011160A (es) 2014-02-28 2017-04-27 Tensha Therapeutics Inc Tratamiento de afecciones asociadas con la hiperinsulinemia.

Also Published As

Publication number Publication date
AR105124A1 (es) 2017-09-06
AU2016283020A1 (en) 2018-01-04
US20180193350A1 (en) 2018-07-12
JP2018520124A (ja) 2018-07-26
CA2989313A1 (en) 2016-12-29
WO2016210275A1 (en) 2016-12-29
EP3314005A1 (en) 2018-05-02
IL256186A (en) 2018-02-28
MA42249A (fr) 2018-05-02
BR112017028178A2 (pt) 2018-08-28
MX2017016337A (es) 2018-11-22
KR20180035785A (ko) 2018-04-06
CN107787227A (zh) 2018-03-09

Similar Documents

Publication Publication Date Title
IL259783A (en) Methods of treatment of malignant diseases
IL283258A (en) A preparation for the treatment of hypothyroidism
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
IL259996A (en) Combinations for cancer treatment
ZA201706257B (en) Treatment of wood
HK1258611A1 (zh) 腹水的治療
HK1252062A1 (zh) Nut中線癌的治療
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
HK1244711A1 (zh) Hmgb1介導的炎症的治療
PL3122349T3 (pl) Kompozycje do leczenia samotrawienia
HK1252245A1 (zh) 用於治療癌症的核苷酸
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
GB201408297D0 (en) Treatment of cancer
GB201508841D0 (en) Treatment
GB201508385D0 (en) Metal treatment
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
GB201412010D0 (en) Treatment of hypertransaminasemia
IL255167A0 (en) Compounds for the treatment of cancer
GB201512139D0 (en) Methods of treatment
GB201510870D0 (en) Treatment of infarction
GB201503008D0 (en) Treatment
GB201417456D0 (en) Treatment of cancer
SG10201913141UA (en) Treatment of alphavirus-induced inflammation
GB201512723D0 (en) Treatment of cancer